Here, we used the US Department of Veterans Affairs databases to build a cohort of people with diabetes who initiated GLP-1RA ( n = 215,970) and compared them to those who initiated sulfonylureas ( n = 159,465), dipeptidyl peptidase 4 (DPP4) inhibitors ( n = 117,989) or sodiumglucose cotransporter-2 (SGLT2) inhibitors ( n = 258,614), a control group composed of an equal proportion of individuals initiating sulfonylureas, DPP4 inhibitors and SGLT2 inhibitors ( n = 536,068), and a control group of 1,203,097 individuals who continued use of non-GLP-1RA antihyperglycemics (usual care)
Your health and weight loss journey begins now
A dramatic ROS production sustains NF-B pathway, which is accompanied by Nrf2 inactivation, resulting in an amplification of the inflammatory loop
In the SURMOUNT trials, night sweats were more common during dose escalation phases (when patients moved from 2.5 mg to 5 mg to 10 mg weekly injections) rather than at maintenance doses
What Role Do Needle Size, Technique, and Injection Devices Play in Bruising
Both morning and evening injections are equally effective
